GV and Alexandria have taken part in a $191m round to launch Maze Therapeutics with scientific co-founders from multiple universities such as Harvard and Stanford.

US-based biotechnology developer Maze Therapeutics launched yesterday with $191m in funding provided by a consortium featuring GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet.

Alexandria Venture Investments, the investment arm of life science real estate trust Alexandria Real Estate Equities, also participated in the round co-led by Third Rock Ventures and Arch Venture Partners.

Foresite Capital, Casdin Capital and several undisclosed investors filled out the round.

Maze Therapeutics will focus on genetic modifiers – genes that affect the severity of a disease – and develop drugs that target such modifiers to treat disorders.

The company will use the funding to develop its platform and to advance three programs – a gene therapy for an unspecified neurodegenerative disease, a treatment for an undisclosed condition and a third asset “in a totally different therapeutic space”, Charles Homcy, founder and interim CEO of Maze told Fierce Biotech.

Maze hopes to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).